Table 1 Proportion of patients who underwent Crohn’s disease-related surgery and time to first Crohn’s disease-related surgery
Total N = 1,122 | Vedolizumab N = 578 | Ustekinumab N = 544 | p value | |
|---|---|---|---|---|
CD-related surgery, n (%) | 96 (8.56) | 42 (7.27) | 54 (9.93) | 0.111 |
Time from index date to first CD-related surgery, days | ||||
Mean (SD) | 207.17 (177.35) | 229.86 (188.91) | 189.52 (167.46) | 0.271 |
Median (Q1–Q3) | 158.00 (57.00–310.50) | 170.00 (77.00–324.00) | 141.50 (49.00–258.00) |